ALK-Abelló A/S (LON:0OIR)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 5.61B +22.5% |
| Revenue (ttm) | 766.51M +14.9% |
| Net Income | 149.54M +36.6% |
| EPS | 0.68 +38.3% |
| Shares Out | n/a |
| PE Ratio | 37.48 |
| Forward PE | 32.24 |
| Dividend | 0.19 (0.73%) |
| Ex-Dividend Date | Mar 17, 2026 |
| Volume | 1,899 |
| Open | 220.80 |
| Previous Close | 220.60 |
| Day's Range | 220.80 - 221.90 |
| 52-Week Range | 172.70 - 271.60 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2026 |
About ALK-Abelló
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays ... [Read more]
Financial Performance
In 2025, ALK-Abelló's revenue was 6.31 billion, an increase of 14.00% compared to the previous year's 5.54 billion. Earnings were 1.20 billion, an increase of 46.87%.
Financial numbers in DKK Financial StatementsNews
EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis
ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy ® 1 mg, the first and only needle-free adrenaline treatment for anaph...
Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap
New scientific data reveal serious shortcomings in the real-world management of anaphylaxis, with findings from two multi-country surveys suggesting that EURneffy ®—the first and only approved needle-...
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the f...
ALK-Abello initiated with a Buy at Berenberg
Berenberg initiated coverage of ALK-Abello (AKBLF) with a Buy rating and DKK 305 price target The firm says ALK is the global market leader in allergy immunotherapy. Published first on…
ALK-Abelló Quarterly report: Q1 2026
ALK-Abelló has published its Q1 2026 quarterly earnings report on May 5, 2026.
ALK-Abelló Slides: Q1 2026
ALK-Abelló has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
ALK-Abelló Earnings Call Transcript: Q1 2026
Q1 saw revenue and EBIT exceed guidance, driven by strong tablet and anaphylaxis sales, especially in Europe and North America. Upgraded full-year outlook reflects continued momentum, with significant investments in growth and R&D, and key advances in peanut allergy and neffy.
ALK-Abelló Quarterly report: Q1 2026
ALK-Abelló has published its Q1 2026 quarterly earnings report on May 4, 2026.
ALK-Abelló Slides: Q1 2026
ALK-Abelló has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
Three-month interim report (Q1) 2026 (unaudited)
ALK delivers 18% organic revenue growth with operating profit (EBIT) up 22% in Q1 Q1 saw broad-based growth across key categories and regions with sustained, strong momentum in tablet sales in Europe ...
ALK upgrades its full-year outlook
Inside Information ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong underlying momentum for tablet sales and red...
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults. Clear dose-d...
Annual General Meeting in ALK-Abelló A/S held on 16 March 2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): ALK-Abelló A/S held its Annual General Meeting on 16 March 2026. The Annual General Meeting transacted the following business: Approval of the annual report ...
ALK-Abelló Transcript: AGM 2026
Strong revenue and profit growth in 2025 enabled a resumed dividend and continued investment in R&D, production, and sustainability. All board proposals, including an updated remuneration policy and board re-elections, were approved. Shareholders discussed production, AI, and market expansion.
ALK-Abelló Annual report: Q4 2025
ALK-Abelló has published its Q4 2025 annual report on February 23, 2026.
ALK-Abelló Slides: Q4 2025
ALK-Abelló has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 23, 2026.
ALK-Abelló Earnings Call Transcript: Q4 2025
Strong 2025 results with 15% revenue growth, 26% EBIT margin, and robust expansion in tablets and anaphylaxis products. 2026 guidance targets 11–15% revenue growth, continued double-digit tablet and anaphylaxis sales, and ongoing investment in R&D and infrastructure.
ALK-Abelló Annual report: Q4 2025
ALK-Abelló has published its Q4 2025 annual report on February 20, 2026.
ALK-Abelló Slides: Q4 2025
ALK-Abelló has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 20, 2026.
Invitation to the presentation of ALK's annual report 2025 on Friday, 20 February 2026
ALK (ALKB:DC / OMX: ALK B) will publish its annual report for 2025 in the morning on Friday, 20 February 2026. Later on the same day, the company will host a presentation for investors and analysts at...
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP') of the European Medicines Agency has adopted a positive opinion recommend...
ALK-Abelló Quarterly report: Q3 2025
ALK-Abelló has published its Q3 2025 quarterly earnings report on November 13, 2025.
ALK-Abelló Slides: Q3 2025
ALK-Abelló has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 13, 2025.
ALK-Abelló Earnings Call Transcript: Q3 2025
Q3 delivered double-digit revenue and EBIT growth, driven by strong pediatric tablet launches, new partnerships, and robust performance across all regions and product lines. The full-year outlook was raised, with continued investment in growth initiatives and a strong balance sheet.
ALK-Abelló Quarterly report: Q3 2025
ALK-Abelló has published its Q3 2025 quarterly earnings report on November 13, 2025.